Statistical analyses were performed using Stata/IC version 15 (StataCorp, College station, TX, USA)
At 48 weeks, the least-squares mean percentage change in body weight in the retatrutide groups was -8.7% (1 mg), -17.1% (combined 4 mg), -22.8% (combined 8 mg), and an astounding -24.2% (12 mg), compared to -2.1% in the placebo group
For individuals with eating disorders, these side effects can compound existing gastrointestinal problems and cause serious medical complications
Completion rates are high, with 81% of members finishing the first year and 70% enrolling in a second year, suggesting strong engagement and program adherence
Baseline Assessment IGF-1 serum levels Fasting glucose and HbA1c Comprehensive Metabolic Panel Cancer screening when appropriate Complete Blood Count Follow-Up Monitoring Monthly fasting glucose IGF-1 levels at 46 weeks Clinical assessment during follow-up visits Metabolic monitoring every three months Clinical Evidence Summary Several published studies support the potential applications of IGF-1 LR3 in muscle development, tissue repair, and metabolic optimization